Stephen Gardner to Drug Administration Schedule
This is a "connection" page, showing publications Stephen Gardner has written about Drug Administration Schedule.
Connection Strength
0.114
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.102
-
Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17.
Score: 0.012